GlassScriptPhysician profile
Pankaj Khullar
NPI 1497035588
$13,719.17
in general payments reported to CMS, 2019-2025
14 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $18.75 · 2021: $307 · 2022: $5,847 · 2023: $2,396 · 2024: $865 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095 · Travel and Lodging: $1,903 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.39 |
| Travel and Lodging | $1,902.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $6,859.71 | 2019-2023 | Diamondback Peripheral |
| Abbott Laboratories | $3,284.62 | 2019-2024 | Diamondback Peripheral, Absolute Pro |
| Angiodynamics, INC. | $2,528.82 | 2023-2025 | Angiovac, Alphavac |
| Heartflow, INC. | $302.76 | 2021-2023 | Ffrct |
| Teleflex LLC | $213.82 | 2021-2024 | Guideliner |
| Bard Peripheral Vascular, INC. | $180.41 | 2025 | Rotarexs 6 F X 135 Cm |
| Astrazeneca Pharmaceuticals LP | $129.36 | 2019 | |
| Inari Medical, INC. | $85.46 | 2019 | |
| Amarin Pharma, INC. | $38.13 | 2019-2020 | |
| Abiomed | $24.29 | 2025 | |
| Tactile Systems Technology INC | $23.28 | 2025 | Nimbl, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $22.09 | 2021 | |
| Merck Sharp & Dohme LLC | $14.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Khullar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.